APAF1 (apoptotic peptidase activating factor) was reported as a potential drug target for neurodegenerative diseases and APAF1 dominant negative inhibitor can prevent MPTP toxicity as antiapoptotic gene therapy for Parkinson’s disease38. This evidence concerns the gene APAF1 and neurodegenerative disease.